“Cancer therapies based on targeted protein degradation – lessons learned with lenalidomide.”
Jan, M., A. S. Sperling and B. L. EbertNat Rev Clin Oncol, 2021.
Nat Rev Clin Oncol, 2021.
“Targeting ubiquitin-specific protease-7 in plasmacytoid dendritic cells triggers anti-myeloma immunity.”
Ray, A., T. Du, Y. Song, S. J. Buhrlage, D. Chauhan and K. C. AndersonLeukemia, 2021.
“Identification of novel anti-tumor therapeutic target via proteomic characterization of ubiquitin receptor ADRM1/Rpn13.”
Song, Y., T. Du, A. Ray, K. Chauhan, M. Samur, N. Munshi, D. Chauhan and K. C. AndersonBlood Cancer J, 2021.
“BCAS1 expression defines a population of early myelinating oligodendrocytes in multiple sclerosis lesions.”
Fard, M. K., F. van der Meer, P. Sanchez, L. Cantuti-Castelvetri, S. Mandad, S. Jakel, E. F. Fornasiero, S. Schmitt, M. Ehrlich, L. Starost, T. Kuhlmann, C. Sergiou, V. Schultz, C. Wrzos, W. Bruck, H. Urlaub, L. Dimou, C. Stadelmann and M. SimonsSci Transl Med, 2017.
“Preclinical validation of Alpha-Enolase (ENO1) as a novel immunometabolic target in multiple myeloma.”
Ray, A., Y. Song, T. Du, D. Chauhan and K. C. AndersonOncogene, 2020.
“SARS-CoV-2 in multiple myeloma: initial observation and management.”
Manasanch, E. E., V. Mulanovich, J. G. Manzano, M. S. Gaeta, M. Becnel, G. P. Kaufman, H. C. Lee, B. Amini, S. K. Thomas, S. P. Iyer, D. M. Weber, Z. Berkova, C. R. Flowers, R. Z. Orlowski and K. K. PatelLeuk Lymphoma, 2020.
“Clonal hematopoiesis is associated with adverse outcomes in multiple myeloma patients undergoing transplant.”
Mouhieddine, T. H., A. S. Sperling, R. Redd, J. Park, M. Leventhal, C. J. Gibson, S. Manier, A. H. Nassar, M. Capelletti, D. Huynh, M. Bustoros, R. Sklavenitis-Pistofidis, S. Tahri, K. Hornburg, H. Dumke, M. M. Itani, C. J. Boehner, C. J. Liu, S. H. AlDubayan, B. Reardon, E. M. Van Allen, J. J. Keats, C. Stewart, S. Mehr, D. Auclair, R. L. Schlossman, N. C. Munshi, K. C. Anderson, D. P. Steensma, J. P. Laubach, P. G. Richardson, J. Ritz, B. L. Ebert, R. J. Soiffer, L. Trippa, G. Getz, D. S. Neuberg and I. M. GhobrialNat Commun, 2020.
“The JAK-STAT pathway regulates CD38 on myeloma cells in the bone marrow microenvironment: therapeutic implications.”
Ogiya, D., J. Liu, H. Ohguchi, K. Kurata, M. K. Samur, Y. T. Tai, S. Adamia, K. Ando, T. Hideshima and K. C. AndersonBlood, 2020.
“Minimal Residual Disease Negativity Does Not Overcome Poor Prognosis in High-Risk Multiple Myeloma: A Single-Center Retrospective Study.”
Kunacheewa, C., H. C. Lee, K. Patel, S. Thomas, B. Amini, S. Srour, Q. Bashir, Y. Nieto, M. H. Qazilbash, D. M. Weber, L. Feng, R. Z. Orlowski, P. Lin and E. E. ManasanchClin Lymphoma Myeloma Leuk, 2020.
“High-risk smoldering myeloma versus early detection of multiple myeloma: Current models, goals of therapy, and clinical implications.”
Kunacheewa, C. and E. E. ManasanchBest Pract Res Clin Haematol, 2020.
“Preclinical evaluation of CD8+ anti-BCMA mRNA CAR T cells for treatment of multiple myeloma.”
Lin, L., S. F. Cho, L. Xing, K. Wen, Y. Li, T. Yu, P. A. Hsieh, H. Chen, M. Kurtoglu, Y. Zhang, C. Andrew Stewart, N. Munshi, K. C. Anderson and Y. T. TaiLeukemia, 2020.
“Phase I/II study of high dose pomalidomide with G-CSF support and dexamethasone in patients with relapsed/refractory multiple myeloma.”
Manasanch, E. E., P. Jain, W. Chen, O. Oriabure, M. Badillo, L. Feng, Z. Berkova, R. Z. Orlowski and M. WangAm J Hematol, 2020.
“Phase I/Ib study of carfilzomib and panobinostat with or without dexamethasone in patients with relapsed/refractory multiple myeloma.”
Manasanch, E. E., J. J. Shah, H. C. Lee, D. M. Weber, S. K. Thomas, B. Amini, J. Olsem, B. Crumpton, A. Morphey, Z. Berkova, L. Feng and R. Z. OrlowskiHaematologica, 2019.
“Patterns of substrate affinity, competition, and degradation kinetics underlie biological activity of thalidomide analogs.”
Sperling, A. S., M. Burgess, H. Keshishian, J. A. Gasser, S. Bhatt, M. Jan, M. Slabicki, R. S. Sellar, E. C. Fink, P. G. Miller, B. J. Liddicoat, Q. L. Sievers, R. Sharma, D. N. Adams, E. A. Olesinski, M. Fulciniti, N. D. Udeshi, E. Kuhn, A. Letai, N. C. Munshi, S. A. Carr and B. L. EbertBlood, 2019.
“B cell maturation antigen (BCMA)-based immunotherapy for multiple myeloma.”
Tai, Y. T. and K. C. AndersonExpert Opin Biol Ther, 2019.
“Ubiquitin-activating enzyme inhibition induces an unfolded protein response and overcomes drug resistance in myeloma.”
Zhuang, J., F. Shirazi, R. K. Singh, I. Kuiatse, H. Wang, H. C. Lee, Z. Berkova, A. Berger, M. Hyer, N. Chattopadhyay, S. Syed, J. Q. Shi, J. Yu, V. Shinde, S. Tirrell, R. J. Jones, Z. Wang, R. E. Davis and R. Z. OrlowskiBlood, 2019.